Oncolytics Biotech (NASDAQ:ONCY) Stock Price Down 0.7%

Oncolytics Biotech Inc. (NASDAQ:ONCY) shares dropped 0.7% on Monday . The stock traded as low as $0.93 and last traded at $0.95. Approximately 78,988 shares changed hands during mid-day trading, a decline of 70% from the average daily volume of 266,283 shares. The stock had previously closed at $0.96.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Oncolytics Biotech in a report on Wednesday, August 21st.

Oncolytics Biotech Trading Down 0.7 %

The business’s fifty day moving average is $0.99 and its 200 day moving average is $1.04.

Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. During the same quarter last year, the business earned ($0.09) earnings per share. Analysts predict that Oncolytics Biotech Inc. will post -0.29 EPS for the current year.

Institutional Investors Weigh In On Oncolytics Biotech

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC acquired a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech at the end of the most recent reporting period. Institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.